A Phase 4 interventional study of Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321) in Macular Edema, sponsored by Bayer. Completed at 76 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-10.
Sponsored by Bayer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies testing aflibercept in Macular Edema — 1 open to participants now, 3 under way, 1 of them phase 3. aflibercept · Macular Edema.
Among the 53 studies testing aflibercept in Macular Edema, this one is the 3rd largest by enrollment, is one of 11 that started in 2015, is one of 26 in phase 4, and was the 22nd registered.
758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.
Browse Macular Edema studies →1 of the 53 studies testing aflibercept in Macular Edema is open now, in 1 country. Recruiting first, the newest first:
CMH Multan Institute of Medical Sciences · Sites in Pakistan
Ages 30–60
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 44 Macular Edema studies recruiting now, 31 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 12 · Phase 4 26
First in 2006; this study’s year is marked. 11 started in 2015.
This study's enrollment of 560 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 49 across the 53 interventional studies. Of the 36 that completed or were terminated, 18 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 53 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
16 studies in Macular Edema by Bayer: none open now, 1 under way, none of them phase 3. Of 15 finished, 8 (53%) have results posted.
Among the 16 studies in Macular Edema by Bayer, this one is the 2nd largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2015, is one of 3 in phase 4, and was the 8th registered.
Bayer’s Macular Edema studies by the year they started, since 2009.
1 of the studies testing aflibercept in Macular Edema that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02645266McMaster UniversityMean Visual Acuity Changes Following Five Injections of Aflibercept | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 53 studies testing aflibercept in Macular Edema, from their registry updates:
Among Bayer’s 16 in Macular Edema:
This tab as a report to print or save as PDF → With an account.
To evaluate the change in quality of life (NEI VFQ 25) in subjects with DME during the first year of treatment with aflibercept according to the EU Label.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Aflibercept treatment in subjects with diabetic macular edema (DME)
Drug: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
2 mg aflibercept administered every 8 weeks following 5 initial monthly doses Intravitreal (IVT) injection
Change From Baseline to Week 52 in NEI VFQ-25 Total Score
National eye institute 25-item visual function questionnaire (NEI VFQ-25) is a condition-specific measure which was designed to capture the specific impact of vision loss on health-related quality of life (HRQoL). The calculation for NEI VFQ-25 sub-scale scores and total score was performed according to the "NEI VFQ-25 Scoring Algorithm - August 2000". The NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. In this format scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score.
Time frame: Baseline, Week 52
Change From Baseline to Week 52 in the NEI VFQ 25 Near Activities Subscale
NEI VFQ-25 is a condition-specific measure which was designed to capture the specific impact of vision loss on HRQoL. The calculation for NEI VFQ-25 sub-scale scores and total score was performed according to the "NEI VFQ-25 Scoring Algorithm - August 2000". Items within each sub-scale are averaged together to create the 12 sub-scale Scores. Items that are left blank (missing data) are not taken into account when calculating the scale scores. Sub-scales with at least one item answered can be used to generate a sub-scale score. Hence, scores represent the average for all items in the subscale that the respondent answered.The NEI VFQ-25 near activities subscale was scored from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf.
Time frame: Baseline, Week 52
Change From Baseline to Week 52 in the NEI VFQ 25 Distant Activities Subscale
NEI VFQ-25 is a condition-specific measure which was designed to capture the specific impact of vision loss on HRQoL. The calculation for NEI VFQ-25 sub-scale scores and total score was performed according to the "NEI VFQ-25 Scoring Algorithm - August 2000". Items within each sub-scale are averaged together to create the 12 sub-scale Scores. Items that are left blank (missing data) are not taken into account when calculating the scale scores. Sub-scales with at least one item answered can be used to generate a sub-scale score. Hence, scores represent the average for all items in the subscale that the respondent answered. The NEI VFQ-25 distant activities subscale was scored from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. Distant activities are defined as activities requiring distance vision, such as recognizing faces or reading street signs.
Time frame: Baseline, Week 52
Change From Baseline to Week 52 in Best Corrected Visual Acuity (BCVA) (Early Treatment Diabetic Retinopathy Study [ETDRS] Letter Score])
Visual function was assessed using the ETDRS protocol (Early Treatment Diabetic Retinopathy Study Research Group 1985) starting at 4 meters. The values might range from 0 to 100. A higher score represents better functioning.
Time frame: Baseline, Week 52
Change From Baseline to Week 52 in Central Retinal Thickness (CRT) Measured by Optical Coherence Tomography (OCT)
Retinal and lesion characteristics were evaluated using spectral domain optical coherence tomography (OCT). For all visits where the OCT procedure was scheduled, images were captured and read by the investigator. All OCTs were electronically archived at the study sites as part of the source documentation.
Time frame: Baseline, Week 52
Proportion of Participants Progressing to Greater or Equal to (>=) 61 on the ETDRS Diabetic Retinopathy Severity Scale (DRSS) as Assessed by Fundus Photography (FP)
The ETDRS DRSS was assessed by FP according to the following scale for both eyes. The following severities are possible. 10 = Diabetic retinopathy (DR) absent, 14 = DR questionable, 15 = DR questionable, 20 = Micro-aneurysms only, 35 = Mild Non-proliferative diabetic retinopathy (NPDR), 43 = Moderate NPDR, 47 = Moderately severe NPDR, 53 = Severe NPDR, 61 = Mild Proliferative diabetic retinopathy (PDR), 65 = Moderate PDR, 71 = High-risk PDR, 75 = High-risk PDR, 81 = Advanced PDR: fundus partially obscured, center of macula attached, 85 = Advanced PDR: posterior fundus obscured, or center of macula detached, 90 = cannot grade, even sufficiently for level 81 or 85.
Time frame: Baseline, Week 52
Change From Baseline in Pre-injection Intraocular Pressure for Study Eye Every 4 Weeks
Intraocular pressure (IOP) was measured using applanation tonometry Goldmann, Tonopen or approved alternative). The same method of intraocular pressure measurement was used in each participant throughout the study. For the measurement of intraocular pressure, a local anesthetic combined with fluorescein was applied topically to the eye being tested (example: one drop of oxybuprocain plus fluorescein). In the below table, pre-injection intraocular pressure for study eye was reported.
Time frame: Baseline, Weeks 4, 8, 12, 16, 24, 32, 40, 48, 52
Change From Baseline in Systolic Blood Pressure at Week 52
Systolic blood pressure was measured in a consistent and standardized way according to locally established practice.
Time frame: Baseline, Week 52
Change From Baseline in Diastolic Blood Pressure at Week 52
Diastolic blood pressure was measured in a consistent and standardized way according to locally established practice.
Time frame: Baseline, Week 52
Change From Baseline in Heart Rate at Week 52
Heart rate was measured in a consistent and standardized way according to locally established practice.
Time frame: Baseline, Week 52
Change From Baseline in Body Temperature at Week 52
Temperature was measured in a consistent and standardized way according to locally established practice.
Time frame: Baseline, Week 52
Study was conducted at multiple study centers in 14 countries, between 19 November 2015 (first participant first visit) and 09 August 2017 (last participant last visit).
| Milestone | Aflibercept |
|---|---|
| Started | 560 |
| Treated | 560 |
| Completed | 529 |
| Not completed | 31 |
| Withdrew: Unspecified other | 3 |
| Withdrew: Adverse event | 6 |
| Withdrew: Lost to follow-up | 5 |
| Withdrew: Withdrawal by participant | 12 |
| Withdrew: Physician decision | 1 |
| Withdrew: Death | 4 |
National eye institute 25-item visual function questionnaire (NEI VFQ-25) is a condition-specific measure which was designed to capture the specific impact of vision loss on health-related quality of life (HRQoL). The calculation for NEI VFQ-25 sub-scale scores and total score was performed according to the "NEI VFQ-25 Scoring Algorithm - August 2000". The NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. In this format scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score.
| score on a scale | Aflibercept |
|---|---|
| Change From Baseline to Week 52 in NEI VFQ-25 Total Score | 6.106 (5.303 to 6.909) |
NEI VFQ-25 is a condition-specific measure which was designed to capture the specific impact of vision loss on HRQoL. The calculation for NEI VFQ-25 sub-scale scores and total score was performed according to the "NEI VFQ-25 Scoring Algorithm - August 2000". Items within each sub-scale are averaged together to create the 12 sub-scale Scores. Items that are left blank (missing data) are not taken into account when calculating the scale scores. Sub-scales with at least one item answered can be used to generate a sub-scale score. Hence, scores represent the average for all items in the subscale that the respondent answered.The NEI VFQ-25 near activities subscale was scored from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf.
| score on a scale | Aflibercept |
|---|---|
| Change From Baseline to Week 52 in the NEI VFQ 25 Near Activities Subscale | 11.370 (10.108 to 12.632) |
NEI VFQ-25 is a condition-specific measure which was designed to capture the specific impact of vision loss on HRQoL. The calculation for NEI VFQ-25 sub-scale scores and total score was performed according to the "NEI VFQ-25 Scoring Algorithm - August 2000". Items within each sub-scale are averaged together to create the 12 sub-scale Scores. Items that are left blank (missing data) are not taken into account when calculating the scale scores. Sub-scales with at least one item answered can be used to generate a sub-scale score. Hence, scores represent the average for all items in the subscale that the respondent answered. The NEI VFQ-25 distant activities subscale was scored from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. Distant activities are defined as activities requiring distance vision, such as recognizing faces or reading street signs.
| score on a scale | Aflibercept |
|---|---|
| Change From Baseline to Week 52 in the NEI VFQ 25 Distant Activities Subscale | 7.331 (6.118 to 8.545) |
Visual function was assessed using the ETDRS protocol (Early Treatment Diabetic Retinopathy Study Research Group 1985) starting at 4 meters. The values might range from 0 to 100. A higher score represents better functioning.
| score on a scale | Aflibercept |
|---|---|
| Change From Baseline to Week 52 in Best Corrected Visual Acuity (BCVA) (Early Treatment Diabetic Retinopathy Study [ETDRS] Letter Score]) | 10.0 (9.5 to 10.6) |
Retinal and lesion characteristics were evaluated using spectral domain optical coherence tomography (OCT). For all visits where the OCT procedure was scheduled, images were captured and read by the investigator. All OCTs were electronically archived at the study sites as part of the source documentation.
| microns | Aflibercept |
|---|---|
| Change From Baseline to Week 52 in Central Retinal Thickness (CRT) Measured by Optical Coherence Tomography (OCT) | -175.38 (-184.93 to -165.82) |
The ETDRS DRSS was assessed by FP according to the following scale for both eyes. The following severities are possible. 10 = Diabetic retinopathy (DR) absent, 14 = DR questionable, 15 = DR questionable, 20 = Micro-aneurysms only, 35 = Mild Non-proliferative diabetic retinopathy (NPDR), 43 = Moderate NPDR, 47 = Moderately severe NPDR, 53 = Severe NPDR, 61 = Mild Proliferative diabetic retinopathy (PDR), 65 = Moderate PDR, 71 = High-risk PDR, 75 = High-risk PDR, 81 = Advanced PDR: fundus partially obscured, center of macula attached, 85 = Advanced PDR: posterior fundus obscured, or center of macula detached, 90 = cannot grade, even sufficiently for level 81 or 85.
| proportion of participants | Aflibercept |
|---|---|
| Proportion of Participants Progressing to Greater or Equal to (>=) 61 on the ETDRS Diabetic Retinopathy Severity Scale (DRSS) as Assessed by Fundus Photography (FP) | 0.4 |
Intraocular pressure (IOP) was measured using applanation tonometry Goldmann, Tonopen or approved alternative). The same method of intraocular pressure measurement was used in each participant throughout the study. For the measurement of intraocular pressure, a local anesthetic combined with fluorescein was applied topically to the eye being tested (example: one drop of oxybuprocain plus fluorescein). In the below table, pre-injection intraocular pressure for study eye was reported.
| millimeter of mercury (mmHg) | Aflibercept |
|---|---|
| Change at Week 4 | -0.4 ± 2.9 |
| Change at Week 8 | -0.3 ± 2.9 |
| Change at Week 12 | -0.5 ± 2.9 |
| Change at Week 16 | -0.3 ± 2.9 |
| Change at Week 24 | -0.2 ± 3.0 |
| Change at Week 32 | -0.1 ± 3.0 |
| Change at Week 40 | 0.0 ± 3.0 |
| Change at Week 48 | 0.0 ± 3.0 |
| Change at Week 52 | 0.1 ± 3.1 |
Systolic blood pressure was measured in a consistent and standardized way according to locally established practice.
| millimeter of mercury (mmHg) | Aflibercept |
|---|---|
| Change From Baseline in Systolic Blood Pressure at Week 52 | -0.1 ± 15.1 |
Diastolic blood pressure was measured in a consistent and standardized way according to locally established practice.
| millimeter of mercury (mmHg) | Aflibercept |
|---|---|
| Change From Baseline in Diastolic Blood Pressure at Week 52 | -0.3 ± 9.9 |
Heart rate was measured in a consistent and standardized way according to locally established practice.
| beats per minute (beats/min) | Aflibercept |
|---|---|
| Change From Baseline in Heart Rate at Week 52 | -1.0 ± 9.5 |
Temperature was measured in a consistent and standardized way according to locally established practice.
| celsius | Aflibercept |
|---|---|
| Change From Baseline in Body Temperature at Week 52 | -0.04 ± 0.41 |
Collected over From start of study treatment up to 30 days after the last injection of study treatment, up to week 52. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aflibercept | 5/560 (0.9%) | 66/560 (11.8%) | 0/560 (0%) |
| Event | Aflibercept |
|---|---|
| PneumoniaInfections and infestations | 6/560 |
| EndophthalmitisInfections and infestations | 3/560 |
| Cerebrovascular accidentNervous system disorders | 3/560 |
| Cardiac failure acuteCardiac disorders | 2/560 |
| Myocardial infarctionCardiac disorders | 2/560 |
| Posterior capsule opacificationEye disorders | 2/560 |
| VitritisEye disorders | 2/560 |
| CellulitisInfections and infestations | 2/560 |
| Diabetic foot infectionInfections and infestations | 2/560 |
| Rib fractureInjury, poisoning and procedural complications | 2/560 |
Safety analysis set (SAF) included all participants who received at least 1 injection of study drug.
| Age, Continuous(years) | Aflibercept |
|---|---|
| Mean | 64.3 ± 9.3 |
| Sex: Female, Male(Participants) | Aflibercept |
|---|---|
| Female | 224 |
| Male | 336 |
| Race (NIH/OMB)(Participants) | Aflibercept |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 4 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 519 |
| More than one race | 0 |
| Unknown or Not Reported | 34 |
| Central Retinal Thickness (CRT)(microns) | Aflibercept |
|---|---|
| Mean | 465.08 ± 136.75 |
| Best Corrected Visual Acuity (BCVA)(score on a scale) | Aflibercept |
|---|---|
| Mean | 61.5 ± 11.0 |
| NEI VFQ-25 total score(score on a scale) | Aflibercept |
|---|---|
| Mean | 70.224 ± 19.221 |
| NEI VFQ-25 near activities subscale(score on a scale) | Aflibercept |
|---|---|
| Mean | 62.967 ± 23.479 |
| NEI VFQ-25 distant activities subscale(score on a scale) | Aflibercept |
|---|---|
| Mean | 71.964 ± 23.973 |
6 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2015 to primary completion in Aug 2017, 20 months.
Results were first posted in Oct 2018, 1 year 2 months after primary completion.
Of 63 phase 4 interventional studies under Macular Edema, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 43. This study's 20 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept